UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(MARK ONE)
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2004
OR
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number: 1-14200
CAREMARK RX, INC.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 63-1151076 | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
211 Commerce Street, Suite 800
Nashville, Tennessee 37201
(Address and zip code of principal executive offices)
(615) 743-6600
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes x No ¨
As of July 31, 2004, the registrant had 465,991,969 shares (including 6,179,927 shares held in trust to be utilized in employee benefit plans) of common stock, par value $.001 per share, issued and outstanding.
FORWARD LOOKING STATEMENTS AND FACTORS THAT MAY AFFECT FUTURE RESULTS
In passing the Private Securities Litigation Reform Act of 1995 (the Reform Act), 15 U.S.C.A. Sections 77z-2 and 78u-5 (Supp. 1996), Congress encouraged public companies to make forward looking statements by creating a safe harbor to protect companies from securities law liability in connection with forward-looking statements. Caremark Rx, Inc. (Caremark Rx) intends to qualify both its written and oral forward-looking statements for protection under the Reform Act and any other similar safe harbor provisions. Unless the context indicates otherwise, the words Company, we, our, and us, whenever used in this Quarterly Report on Form 10-Q, refer collectively to Caremark Rx and its wholly-owned subsidiaries.
Forward-looking statements are defined by the Reform Act. Generally, forward-looking statements include expressed expectations of future events and the assumptions on which these expressed expectations are based. All forward-looking statements are inherently uncertain as they are based on various expectations and assumptions concerning future events, and they are subject to numerous known and unknown risks and uncertainties which could cause actual events or results to differ materially from those projected. Due to such risks and uncertainties, the investment community is urged not to place undue reliance on our written or oral forward-looking statements. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.
Forward-looking statements are contained in this document, primarily under the caption: Managements Discussion and Analysis of Financial Condition and Results of Operations, referred to as MD&A, and in the Notes to Condensed Consolidated Financial Statements appearing under Item 1. Moreover, through our senior management, we may from time to time make forward-looking statements about matters described herein or about other matters concerning us.
There are several factors which could adversely affect our operations and financial results, including, but not limited to, the following:
| | Risks relating to identification of, and competition for, growth and expansion opportunities; |
| | Risks relating to declining reimbursement levels for, or increases in the costs of, products dispensed; |
| | Risks relating to exposure to liabilities in excess of our insurance; |
| | Risks relating to compliance with, or changes in, government regulation and legislation, including, but not limited to, pharmacy licensing requirements, the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and healthcare reform legislation; |
| | Risks relating to adverse developments in any investigation related to the pharmaceutical industry that may be conducted by governmental authorities; |
| | Risks relating to adverse resolution of existing or future lawsuits; |
| | Risks relating to successful integration of AdvancePCS; |
| | Risks relating to our liquidity and capital requirements; and |
| | Risks relating to our ability to successfully terminate leases and other contractual agreements related to our discontinued operations and the outcome of various legal disputes surrounding the closure or sale of our Physician Practice Management (PPM) business. |
More detailed discussions of certain of these risk factors can be found under the captions: Business, Legal Proceedings and Managements Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to Consolidated Financial Statements contained in our Annual Report on Form 10-K for the year ended December 31, 2003, which was filed with the Securities and Exchange Commission on March 9, 2004.
i
CAREMARK RX, INC. AND SUBSIDIARIES
QUARTERLY REPORT ON FORM 10-Q
| Page | ||||
| PART I FINANCIAL INFORMATION | ||||
| Item 1. |
Financial Statements | |||
| Condensed Consolidated Balance Sheets June 30, 2004 (Unaudited) and December 31, 2003 |
2 | |||
| 3 | ||||
| 4 | ||||
| Notes to Condensed Consolidated Financial Statements (Unaudited) | 5 | |||
| Item 2. |
Managements Discussion and Analysis of Financial Condition and Results of Operations | 17 | ||
| Item 3. |
Quantitative and Qualitative Disclosures About Market Risk | 26 | ||
| Item 4. |
Controls and Procedures | 26 | ||
| PART II OTHER INFORMATION | ||||
| Item 1. |
Legal Proceedings | 27 | ||
| Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds | 27 | ||
| Item 4. |
Submission of Matters to a Vote of Security Holders | 28 | ||
| Item 6. |
Exhibits and Reports on Form 8-K | 28 | ||
| 29 | ||||
1
CAREMARK RX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)
| June 30, 2004 |
December 31, 2003 |
|||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 873,236 | $ | 815,328 | ||||
| Accounts receivable, less allowance for doubtful accounts of $46,508 in 2004 and $24,746 in 2003 |
2,052,715 | 669,680 | ||||||
| Inventories |
270,161 | 204,939 | ||||||
| Deferred tax asset, net |
383,508 | 240,978 | ||||||
| Prepaid expenses and other current assets |
25,374 | 15,752 | ||||||
| Total current assets |
3,604,994 | 1,946,677 | ||||||
| Property and equipment, net of accumulated depreciation of $200,912 in 2004 and $164,232 in 2003 |
294,202 | 159,769 | ||||||
| Goodwill |
6,880,906 | 49,171 | ||||||
| Intangible assets, net of accumulated amortization of $25,548 in 2004 and $18,928 in 2003 |
943,016 | 9,273 | ||||||
| Deferred tax asset, net |
| 227,426 | ||||||
| Other non-current assets |
58,524 | 81,312 | ||||||
| Total assets |
$ | 11,781,642 | $ | 2,473,628 | ||||
| LIABILITIES AND STOCKHOLDERS EQUITY | ||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 560,641 | $ | 385,362 | ||||
| Claims and discounts payable |
2,456,880 | 509,713 | ||||||
| Other accrued expenses and liabilities |
287,254 | 158,666 | ||||||
| Income taxes payable |
6,640 | 7,820 | ||||||
| Current portion of long-term debt |
4,000 | 2,500 | ||||||
| Total current liabilities |
3,315,415 | 1,064,061 | ||||||
| Long-term debt, net of current portion |
596,610 | 693,125 | ||||||
| Deferred tax liability |
65,222 | | ||||||
| Other long-term liabilities |
264,690 | 75,804 | ||||||
| Total liabilities |
4,241,937 | 1,832,990 | ||||||
| Commitments and contingencies |
||||||||
| Stockholders equity: |
||||||||
| Common stock, $.001 par value per share; 700,000 shares authorized; |
471 | 269 | ||||||
| Additional paid-in capital |
8,507,866 | 1,762,477 | ||||||
| Unearned stock-based compensation |
(37,391 | ) | | |||||
| Treasury stock 2,905 shares in 2004 and 1,855 shares in 2003 |
(62,391 | ) | (28,782 | ) | ||||
| Shares held in trust 6,205 shares in 2004 and 6,263 shares in 2003 |
(100,034 | ) | (101,103 | ) | ||||
| Accumulated deficit |
(757,826 | ) | (981,233 | ) | ||||
| Accumulated other comprehensive loss |
(10,990 | ) | (10,990 | ) | ||||
| Total stockholders equity |
7,539,705 | 640,638 | ||||||
| Total liabilities and stockholders equity |
$ | 11,781,642 | $ | 2,473,628 | ||||
The accompanying Notes to Condensed Consolidated Financial Statements are an integral part of these
balance sheets.
2
CAREMARK RX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In thousands, except per share amounts)
| Three Months Ended June 30, |
Six Months Ended June 30, | |||||||||||
| 2004 |
2003 |
2004 |
2003 | |||||||||
| Net revenue (1) |
$ | 7,304,442 | $ | 2,204,039 | $ | 10,330,385 | $ | 4,367,835 | ||||
| Operating expenses: |
||||||||||||
| Cost of revenues (1)(2) |
6,894,591 | 2,019,399 | 9,689,402 | 4,011,100 | ||||||||
| Selling, general and administrative expenses |
119,945 | 48,785 | 175,856 | 94,888 | ||||||||
| Depreciation |
24,474 | 10,740 | 37,263 | 20,599 | ||||||||
| Amortization of intangible assets |
12,300 | 18 | 13,359 | 35 | ||||||||
| Interest expense, net |
8,578 | 10,875 | 18,408 | 21,969 | ||||||||
| Stock option expense |
8,266 | | 9,085 | | ||||||||
| Integration and other related expenses |
5,028 | | 15,438 | | ||||||||
| Income before provision for income taxes |
231,260 | 114,222 | 371,574 | 219,244 | ||||||||
| Provision for income taxes |
92,041 | 45,688 | 148,167 | 87,697 | ||||||||
| Net income |
$ | 139,219 | $ | 68,534 | $ | 223,407 | $ | 131,547 | ||||
| Average number of common shares outstanding - basic |
459,817 | 256,391 | 368,785 | 255,864 | ||||||||
| Common stock equivalents - stock options and warrants |
11,110 | 7,215 | 9,635 | 6,832 | ||||||||
| Average number of common shares outstanding - diluted |
470,927 | 263,606 | 378,420 | 262,696 | ||||||||
| Net income per common share - basic |
$ | 0.30 | $ | 0.27 | $ | 0.61 | $ | 0.51 | ||||
| Net income per common share - diluted |
$ | 0.30 | $ | 0.26 | $ | 0.59 | $ | 0.50 | ||||
| (1) | Includes approximately $1.3 billion and $304 million of retail copayments for the three months ended June 30, 2004 and 2003, and approximately $1.8 billion and $615 million of retail copayments for the six months ended June 30, 2004 and 2003, respectively. |
| (2) | Excludes depreciation expense, which is presented separately. |
The accompanying Notes to Condensed Consolidated Financial Statements are an integral part of
these statements.
3
CAREMARK RX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
| Six Months Ended June 30, |
||||||||
| 2004 |
2003 |
|||||||
| Cash flows from continuing operations: |
||||||||
| Net income |
$ | 223,407 | $ | 131,547 | ||||
| Adjustments to reconcile net income to net cash provided by continuing operations: |
||||||||
| Deferred income taxes |
101,252 | 78,058 | ||||||
| Depreciation and amortization |
50,622 | 20,634 | ||||||
| Provision for doubtful accounts |
8,318 | 6,758 | ||||||
| Non-cash interest expense |
1,645 | 1,804 | ||||||
| Writeoff of deferred financing costs |
2,206 | | ||||||
| Stock option expense |
9,085 | | ||||||
| Other non-cash expenses |
249 | 541 | ||||||
| Changes in operating assets and liabilities, net of effects of acquisitions and disposals of businesses |
305,112 | 28,049 | ||||||
| Net cash provided by continuing operations |
701,896 | 267,391 | ||||||
| Cash flows from investing activities: |
||||||||
| Capital expenditures, net |
(31,151 | ) | (26,589 | ) | ||||
| Acquisitions of businesses, net of cash acquired |
(391,021 | ) | (319 | ) | ||||
| Partial liquidation of cost-method investment |
10,382 | | ||||||
| Net cash used in investing activities |
(411,790 | ) | (26,908 | ) | ||||
| Cash flows from financing activities: |
||||||||
| Repayments under credit facilities |
(246,625 | ) | (1,250 | ) | ||||
| Borrowing under new term loan |
150,000 | | ||||||
| Principal payment under AdvancePCS Senior Notes Tender Offer |
(206,810 | ) | | |||||
| Net proceeds from exercise of stock options and retirement of warrants |
113,691 | 39,214 | ||||||
| Purchase of treasury stock |
(33,609 | ) | (6,111 | ) | ||||
| Deferred financing costs |
(3,857 | ) | (100 | ) | ||||
| Securities issuance costs |
(2,729 | ) | | |||||
| Net cash provided by (used in) financing activities |
(229,939 | ) | 31,753 | |||||
| Cash used in discontinued operations |
(2,259 | ) | (53,262 | ) | ||||
| Net increase in cash and cash equivalents |
57,908 | 218,974 | ||||||
| Cash and cash equivalents beginning of period |
815,328 | 306,804 | ||||||
| Cash and cash equivalents end of period |
$ | 873,236 | $ | 525,778 | ||||
| Non-cash investing activities related to the AdvancePCS Acquisition: |
||||||||
| Fair value of non-cash net assets acquired (based on the Companys preliminary purchase price allocation) |
$ | 6,913,941 | ||||||
| Issuance of approximately 191 million shares of common stock |
$ | 6,227,720 | ||||||
| Issuance of replacement stock options for the purchase of approximately 14 million shares of common stock, net of approximately $49.9 million allocated to unearned compensation |
271,909 | |||||||
| Issuance of replacement warrants for the purchase of approximately 902,000 shares of common stock |
15,000 | |||||||
| $ | 6,514,629 | |||||||